Tau-targeted treatment strategies in Alzheimer's disease

Gotz, Jurgen, Ittner, Arne and Ittner, Lars M. (2012) Tau-targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 165 5: 1246-1259. doi:10.1111/j.1476-5381.2011.01713.x

Author Gotz, Jurgen
Ittner, Arne
Ittner, Lars M.
Title Tau-targeted treatment strategies in Alzheimer's disease
Journal name British Journal of Pharmacology   Check publisher's open access policy
ISSN 0007-1188
Publication date 2012-03
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/j.1476-5381.2011.01713.x
Open Access Status DOI
Volume 165
Issue 5
Start page 1246
End page 1259
Total pages 14
Place of publication Chichester, West Sussex, United Kingdom
Publisher John Wiley & Sons
Language eng
Subject 3004 Pharmacology
Abstract With populations ageing worldwide, the need for treating and preventing diseases associated with high age is pertinent. Alzheimer's disease (AD) is reaching epidemic proportions, yet the currently available therapies are limited to a symptomatic relief, without halting the degenerative process that characterizes the AD brain. As in AD cholinergic neurons are lost at high numbers, the initial strategies were limited to the development of acetylcholinesterase inhibitors, and more recently the NMDA receptor antagonist memantine, in counteracting excitotoxicity. With the identification of the protein tau in intracellular neurofibrillary tangles and of the peptide amyloid-β (Aβ) in extracellular amyloid plaques in the AD brain, and a better understanding of their role in disease, newer strategies are emerging, which aim at either preventing their formation and deposition or at accelerating their clearance. Interestingly, what is well established to combat viral diseases in peripheral organs - vaccination - seems to work for the brain as well. Accordingly, immunization strategies targeting Aβ show efficacy in mice and to some degree also in humans. Even more surprising is the finding in mice that immunization strategies targeting tau, a protein that forms aggregates in nerve cells, ameliorates the tau-associated pathology. We are reviewing the literature and discuss what can be expected regarding the translation into clinical practice and how the findings can be extended to other neurodegenerative diseases with protein aggregation in brain.
Keyword Learning and memory
Neuroprotective drugs
Synaptic plasicity
Therapeutic antibodies
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: Queensland Brain Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 47 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 46 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 27 Feb 2014, 12:36:28 EST by Ms Kate Rowe on behalf of Scholarly Communication and Digitisation Service